We use cookies necessary to giving you a better online experience. By using our website you consent to all cookies in accordance with our Privacy Policy.
Yes, I accept
Menu
Search Opener
Stockholm, Sweden

ESTRO 2026

Session

Saturday
May 16
17:00 - 18:00
Viktoria
The oligo-(r)evolution: Long-term evidence and biological frontiers
Aisling Barry, Ireland;
Raphael Bodensohn, Germany
Proffered Papers
Clinical
17:00 - 18:00
Optimizing oligometastatic disease management with circulating tumor DNA: a correlative analysis from the phase II randomized EXTEND trial
Alexander Sherry, USA
-846
17:00 - 18:00
Five-Year Follow-Up of the SABR 5 Trial: Primary Toxicity Analysis of Stereotactic Ablative Radiotherapy for Up to Five Oligometastases
Robert Olson, Canada
-2328
17:00 - 18:00
Early Toxicity of elective nodal RT for Oligorecurrent Pelvic/Paraaortic nodes in Prostate Cancer: a randomised phase 3 trial OLIGOPELVIS-2/GETUG P12.
Stephane Supiot, France
-2263
17:00 - 18:00
Updated clinical outcomes from the RADIOSA randomized phase II trial
Giulia Marvaso, Italy
-4586
17:00 - 18:00
Toxicity profile of sbrt after Bevacizumab in oligometastatic ovarian cancer: a new perspective for radiation oncologists?
Gabriella Macchia, Italy
-691
17:00 - 18:00
Post-hoc analysis of metastasis-free survival (MFS) and Eugonadal MFS in the RADIOSA phase II randomized trial
Giulia Marvaso, Italy
-2857